Health Care [ 12/12 ] | Biotechnology [ 67/73 ]
NASDAQ | Common Stock
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | -2.10 Decreased by -950.00% | -2.00 Decreased by -5.00% |
| Mar 14, 25 | -1.20 Decreased by -471.43% | -2.40 Increased by +50.00% |
| Nov 13, 24 | -4.50 Decreased by -1.86 K% | -4.72 Increased by +4.76% |
| Aug 9, 24 | -5.70 Decreased by -2.01 K% | -5.04 Decreased by -13.10% |
| May 9, 24 | -0.20 Increased by +33.33% | -0.18 Decreased by -11.11% |
| Mar 14, 24 | -0.21 Increased by +43.24% | -0.15 Decreased by -40.00% |
| Nov 9, 23 | -0.23 Increased by +32.35% | -0.24 Increased by +4.17% |
| Aug 10, 23 | -0.27 Increased by +28.95% | -0.27 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -5.55 M Increased by +35.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -6.16 M Increased by +18.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.09 M Increased by +1.16% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.63 M Decreased by -11.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -8.56 M Decreased by -13.78% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 3.75 M Increased by +N/A% | -7.60 M Increased by +2.56% | Decreased by -202.72% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.17 M Increased by +3.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.71 M Decreased by -7.47% | Decreased by N/A% Decreased by N/A% |